1. Universal screening programme for cytomegalovirus infection in the first trimester of pregnancy: study protocol for an observational multicentre study in the area of Barcelona (CITEMB study)
- Author
-
Cristina Martínez, Juliana Esperalba, Concepción Violán, Marta López, Clàudia Fortuny, Pere Torán, Liudmila Liutsko, Rosa García-Sierra, Nerea Maiz, Maria Angeles Sanchez-Durán, Jofre Bielsa-Pascual, Aneta Monika Zientalska, Inés Velasco, Eva Vazquez, Olga Gracia, Aleida Ribas, Nuria Sitja, Maria Nadales, Anna Gonce, Marie Antoinette Frick, Mercedes Guerrero-Martínez, Gemma Falguera-Puig, Roser Gol, Rocio Rodriguez López, Margarita Mendoza Ariza, Meritxell Fors Andreu, Carolina Exposito Moreno, Cristina Garcia López, Elena Scazzocchio Dueñas, Irene Fernández Torm, Loida Lucas Porras, Sara Albero Jiménez, Julia Arquillos Jiménez, Alicia Capel Tatjer, Irene Domínguez García, Yolanda Reyes Nef, Asun Teva Calahorro, Montse Ortiz González, Esther Rebull López, Rocío Garrido Carreño, Sandra Olivera Lindez, Olga Gracia Salazar, Marta Calveiro Hermo, Jordina Munros Feliu, Astrid Francesch Campi, Laia Alcoverro Bedos, Carlota Rodó, Teresa Higueras Sanz, Elida Vázquez, Gema Fernandez Rivas, Ana Sancho Cerro, Karen Castillo-Viteri, Giorgia Sebastiani, María Rosa Escriche Marco, Maria Pilar Sancho Perez, Ana Barluenga Perez-Cossio, Lucia Alcaraz Vidal, Cristina Morote Muñoz, Esther Cerro Hernandez, Marina Raja Carcaña, Marta Xiville Sole, Mercedes Rey Arijón, Miriam Garcia Sanchez, Mª Teresa Sanchez Casado, Natalia Dueñas Herrero, Paula Amoros Ferrer, Pilar Cabrerizo Las Heras, Raquel Martinez Mondejar, Cristina del Viso Lajara, Maria Mercedes Vicente Fernández, Raquel Antón da Silva, Núria Tosquella Roig, Berta Serrano Ejarque, Júlia Mitjans Carrasco, Silvia Martinez Rubiño, and Gemma Prieto Sanchez
- Subjects
Medicine - Abstract
Introduction Congenital cytomegalovirus (cCMV) is the leading cause of non-genetic sensorineural hearing loss and one of the main causes of neurological disability. Despite this, no universal screening programme for cCMV has been implemented in Spain. A recent study has shown that early treatment with valaciclovir, initiated in the first trimester and before the onset of signs in the fetus, reduces the risk of fetal infection. This finding favours the implementation of a universal screening programme for cCMV.The aim of this study is to evaluate the performance of a universal screening programme for cCMV during the first trimester of pregnancy in a primary care setting.Methods and analysis This is an observational multicentre cohort study. The study will be conducted in four primary care settings from the Northern Metropolitan Barcelona area and three related hospitals and will last 3 years and will consist of a recruitment period of 18 months.In their first pregnancy visit, pregnant women will be offered to add a CMV serology test to the first trimester screening tests. Pregnant women with primary infection will be referred to the reference hospital, where they will continue treatment and follow-up according to the clinical protocol of the referral hospital, which includes treatment with valacyclovir. A CMV-PCR will be performed at birth on newborns of mothers with primary infection, and those who are infected will undergo neonatal follow-up for at least 12 months of life.For the analysis, the acceptance rate, the prevalence of primary CMV infections and the CMV seroprevalence in the first trimester of pregnancy will be studied.Ethics and dissemination Ethical approval was obtained from the University Institute Foundation for Primary Health Care Research Jordi Gol i Gurina Ethics Committee 22/097-P dated 27 April 2022.
- Published
- 2023
- Full Text
- View/download PDF